Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

The Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval of Object-Recognition Memory.

Barsegyan A, Atsak P, Hornberger WB, Jacobson PB, van Gaalen MM, Roozendaal B.

Neuropsychopharmacology. 2015 Jul;40(8):1979-89. doi: 10.1038/npp.2015.48. Epub 2015 Feb 11.

2.

Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis.

Malek S, Sample SJ, Schwartz Z, Nemke B, Jacobson PB, Cozzi EM, Schaefer SL, Bleedorn JA, Holzman G, Muir P.

BMC Vet Res. 2012 Oct 4;8:185. doi: 10.1186/1746-6148-8-185.

3.

Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.

Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, Salyers A, Gomez E, Simler G, Lewis LG, Gauvin D, Baker S, Pai M, Tovcimak A, Brown J, Komater V, Fox GB, Decker MW, Jacobson PB, Gopalakrishnan M, Lee CH, Honore P.

Biochem Pharmacol. 2011 Oct 15;82(8):967-76. doi: 10.1016/j.bcp.2011.05.007. Epub 2011 May 17.

PMID:
21620806
4.

Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognition.

Mohler EG, Browman KE, Roderwald VA, Cronin EA, Markosyan S, Scott Bitner R, Strakhova MI, Drescher KU, Hornberger W, Rohde JJ, Brune ME, Jacobson PB, Rueter LE.

J Neurosci. 2011 Apr 6;31(14):5406-13. doi: 10.1523/JNEUROSCI.4046-10.2011.

6.

Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice.

Yang R, Wilcox DM, Haasch DL, Jung PM, Nguyen PT, Voorbach MJ, Doktor S, Brodjian S, Bush EN, Lin E, Jacobson PB, Collins CA, Landschulz KT, Trevillyan JM, Rondinone CM, Surowy TK.

J Biol Chem. 2007 Aug 3;282(31):22765-74. Epub 2007 Jun 5.

7.

Hepatic knockdown of stearoyl-CoA desaturase 1 via RNA interference in obese mice decreases lipid content and changes fatty acid composition.

Xu H, Wilcox D, Nguyen P, Voorbach M, Smith H, Brodjian S, Suhar T, Reilly RM, Jacobson PB, Collins CA, Landschulz K, Surowy TK.

Front Biosci. 2007 May 1;12:3781-94.

PMID:
17485339
8.

Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.

Rohde JJ, Pliushchev MA, Sorensen BK, Wodka D, Shuai Q, Wang J, Fung S, Monzon KM, Chiou WJ, Pan L, Deng X, Chovan LE, Ramaiya A, Mullally M, Henry RF, Stolarik DF, Imade HM, Marsh KC, Beno DW, Fey TA, Droz BA, Brune ME, Camp HS, Sham HL, Frevert EU, Jacobson PB, Link JT.

J Med Chem. 2007 Jan 11;50(1):149-64.

PMID:
17201418
9.

Parallel strategies for the preparation and selection of liver-targeted glucocorticoid receptor antagonists.

Backes BJ, Hamilton GL, Nguyen P, Wilcox D, Fung S, Wang J, Grynfarb M, Goos-Nilsson A, Jacobson PB, von Geldern TW.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):40-4. Epub 2006 Oct 5.

PMID:
17070047
10.

Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile.

Xu H, Wilcox D, Nguyen P, Voorbach M, Suhar T, Morgan SJ, An WF, Ge L, Green J, Wu Z, Gimeno RE, Reilly R, Jacobson PB, Collins CA, Landschulz K, Surowy T.

Biochem Biophys Res Commun. 2006 Oct 13;349(1):439-48. Epub 2006 Aug 22.

PMID:
16935266
11.

Selective antagonism of the hepatic glucocorticoid receptor reduces hepatic glucose production.

Edgerton DS, Jacobson PB, Opgenorth TJ, Zinker B, Beno D, von Geldern T, Ohman L, Scott M, Neal D, Cherrington AD.

Metabolism. 2006 Sep;55(9):1255-62.

PMID:
16919547
12.

Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.

Xin Z, Serby MD, Zhao H, Kosogof C, Szczepankiewicz BG, Liu M, Liu B, Hutchins CW, Sarris KA, Hoff ED, Falls HD, Lin CW, Ogiela CA, Collins CA, Brune ME, Bush EN, Droz BA, Fey TA, Knourek-Segel VE, Shapiro R, Jacobson PB, Beno DW, Turner TM, Sham HL, Liu G.

J Med Chem. 2006 Jul 27;49(15):4459-69.

PMID:
16854051
13.

Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice.

Bush EN, Shapiro R, Brune ME, Knourek-Segel VE, Droz BA, Fey T, Lin E, Jacobson PB.

Endocrine. 2006 Apr;29(2):375-81.

PMID:
16785615
14.

2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists.

Serby MD, Zhao H, Szczepankiewicz BG, Kosogof C, Xin Z, Liu B, Liu M, Nelson LT, Kaszubska W, Falls HD, Schaefer V, Bush EN, Shapiro R, Droz BA, Knourek-Segel VE, Fey TA, Brune ME, Beno DW, Turner TM, Collins CA, Jacobson PB, Sham HL, Liu G.

J Med Chem. 2006 Apr 20;49(8):2568-78.

PMID:
16610800
15.

Distinctions and contradistinctions between antiobesity histamine H(3) receptor (H (3)R) antagonists compared to cognition-enhancing H (3) receptor antagonists.

Hancock AA, Bitner RS, Krueger KM, Otte S, Nikkel AL, Fey TA, Bush EN, Dickinson RW, Shapiro R, Knourek-Segel V, Droz BA, Brune ME, Jacobson PB, Cowart MD, Esbenshade TA.

Inflamm Res. 2006 Apr;55 Suppl 1:S42-4. No abstract available.

PMID:
16547814
16.

Delivery of RNAi reagents in murine models of obesity and diabetes.

Wilcox DM, Yang R, Morgan SJ, Nguyen PT, Voorbach MJ, Jung PM, Haasch DL, Lin E, Bush EN, Opgenorth TJ, Jacobson PB, Collins CA, Rondinone CM, Surowy T, Landschulz KT.

J RNAi Gene Silencing. 2006 Nov 29;3(1):225-36.

17.

Rapamycin analogs with reduced systemic exposure.

Wagner R, Mollison KW, Liu L, Henry CL, Rosenberg TA, Bamaung N, Tu N, Wiedeman PE, Or Y, Luly JR, Lane BC, Trevillyan J, Chen YW, Fey T, Hsieh G, Marsh K, Nuss M, Jacobson PB, Wilcox D, Carlson RP, Carter GW, Djuric SW.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5340-3. Epub 2005 Sep 26.

PMID:
16185865
18.

Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.

Link JT, Sorensen B, Patel J, Grynfarb M, Goos-Nilsson A, Wang J, Fung S, Wilcox D, Zinker B, Nguyen P, Hickman B, Schmidt JM, Swanson S, Tian Z, Reisch TJ, Rotert G, Du J, Lane B, von Geldern TW, Jacobson PB.

J Med Chem. 2005 Aug 11;48(16):5295-304.

PMID:
16078847
19.

Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.

Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB.

Inflamm Res. 2005 Apr;54 Suppl 1:S27-9. No abstract available.

PMID:
15928821
20.

Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.

Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, Fey T, Goos-Nilsson A, Grynfarb M, Barkhem T, Marsh K, Beno DW, Nga-Nguyen B, Kym PR, Link JT, Tu N, Edgerton DS, Cherrington A, Efendic S, Lane BC, Opgenorth TJ.

J Pharmacol Exp Ther. 2005 Jul;314(1):191-200. Epub 2005 Mar 22.

21.

In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.

Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB.

Basic Clin Pharmacol Toxicol. 2004 Sep;95(3):144-52.

22.

Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.

von Geldern TW, Tu N, Kym PR, Link JT, Jae HS, Lai C, Apelqvist T, Rhonnstad P, Hagberg L, Koehler K, Grynfarb M, Goos-Nilsson A, Sandberg J, Osterlund M, Barkhem T, Höglund M, Wang J, Fung S, Wilcox D, Nguyen P, Jakob C, Hutchins C, Färnegårdh M, Kauppi B, Ohman L, Jacobson PB.

J Med Chem. 2004 Aug 12;47(17):4213-30. Erratum in: J Med Chem. 2005 Apr 7;48(7):2724.

PMID:
15293993
23.

Histamine H(3) antagonists in models of obesity.

Hancock AA, Bush EN, Jacobson PB, Faghih R, Esbenshade TA.

Inflamm Res. 2004 Mar;53 Suppl 1:S47-8. Epub 2004 Mar 5. No abstract available.

PMID:
15054613
24.

Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.

Kym PR, Kort ME, Coghlan MJ, Moore JL, Tang R, Ratajczyk JD, Larson DP, Elmore SW, Pratt JK, Stashko MA, Falls HD, Lin CW, Nakane M, Miller L, Tyree CM, Miner JN, Jacobson PB, Wilcox DM, Nguyen P, Lane BC.

J Med Chem. 2003 Mar 13;46(6):1016-30.

PMID:
12620078
25.

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN.

Mol Endocrinol. 2003 May;17(5):860-9. Epub 2003 Feb 13.

PMID:
12586843
26.

Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.

Elmore SW, Coghlan MJ, Anderson DD, Pratt JK, Green BE, Wang AX, Stashko MA, Lin CW, Tyree CM, Miner JN, Jacobson PB, Wilcox DM, Lane BC.

J Med Chem. 2001 Dec 6;44(25):4481-91.

PMID:
11728194
27.

Effect of a short-term in vitro exposure to the marine toxin domoic acid on viability, tumor necrosis factor-alpha, matrix metalloproteinase-9 and superoxide anion release by rat neonatal microglia.

Mayer AM, Hall M, Fay MJ, Lamar P, Pearson C, Prozialeck WC, Lehmann VK, Jacobson PB, Romanic AM, Uz T, Manev H.

BMC Pharmacol. 2001;1:7. Epub 2001 Oct 2.

28.
31.

Streptococcal cell wall-induced arthritis. Requirements for neutrophils, P-selectin, intercellular adhesion molecule-1, and macrophage-inflammatory protein-2.

Schimmer RC, Schrier DJ, Flory CM, Dykens J, Tung DK, Jacobson PB, Friedl HP, Conroy MC, Schimmer BB, Ward PA.

J Immunol. 1997 Oct 15;159(8):4103-8.

PMID:
9379001
33.

Anti-inflammatory properties of Gö 6850: a selective inhibitor of protein kinase C.

Jacobson PB, Kuchera SL, Metz A, Schächtele C, Imre K, Schrier DJ.

J Pharmacol Exp Ther. 1995 Nov;275(2):995-1002.

PMID:
7473193
34.

Regulation of CD11b/CD18 expression in human neutrophils by phospholipase A2.

Jacobson PB, Schrier DJ.

J Immunol. 1993 Nov 15;151(10):5639-52.

PMID:
8228253
37.

Inactivation of human synovial fluid phospholipase A2 by the marine natural product, manoalide.

Jacobson PB, Marshall LA, Sung A, Jacobs RS.

Biochem Pharmacol. 1990 May 15;39(10):1557-64.

PMID:
2337412
38.

A modern concept of the treatment of common external diseases of the eye.

JACOBSON PB.

J Maine Med Assoc. 1953 Apr;44(4):91-4; passim. No abstract available.

PMID:
13045048

Supplemental Content

Loading ...
Support Center